RLYB
Rallybio Corp
Key Financials
Revenue
$858000
↑ 43.0%
Net Income
$-8978000
↑ 84.5%
Operating Income
$-33064000
↑ 45.3%
Total Assets
$62.3M
↓ 8.6%
EPS (Diluted)
$-1.59
↓ 19.5%
Total Liabilities
$4.3M
↓ 33.3%
Shareholders' Equity
$58.0M
↓ 6.0%
Cash & Equivalents
$31.4M
↑ 125.7%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 5/15/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| SCHEDULE 13G | 5/15/2026 | View on SEC |
| SCHEDULE 13G | 5/15/2026 | View on SEC |
| SCHEDULE 13G | 5/15/2026 | View on SEC |
| 4 | 5/13/2026 | View on SEC |
| 10-Q | 5/13/2026 | View on SEC |
| 4 | 5/6/2026 | View on SEC |
| 3 | 5/6/2026 | View on SEC |
| SCHEDULE 13D/A | 5/6/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | RLYB |
| Company Name | Rallybio Corp |
| CIK | 1739410 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 203- 859-3820 |